Advertisement

Timing of neuroendocrine responses and effect of m-CPP and fenfluramine plasma levels in OCD

  • Eric Hollander
    Correspondence
    Address reprint requests to Eric Hollander, M.D., N.Y.S. Psychiatric Institute, 722 W. 168th Street, New York, New York 10032
    Footnotes
    Affiliations
    From the Department of Psychiatry, College of Physicians and Surgeons of Columbia University and the OCD Biological Studies Program, NYS Psychiatric Institute, New York, NY, USA
    Search for articles by this author
  • Lisa J. Cohen
    Footnotes
    Affiliations
    From the Department of Psychiatry, College of Physicians and Surgeons of Columbia University and the OCD Biological Studies Program, NYS Psychiatric Institute, New York, NY, USA
    Search for articles by this author
  • Concetta DeCaria
    Footnotes
    Affiliations
    From the Department of Psychiatry, College of Physicians and Surgeons of Columbia University and the OCD Biological Studies Program, NYS Psychiatric Institute, New York, NY, USA
    Search for articles by this author
  • Jihad B. Saoud
    Footnotes
    Affiliations
    From the Department of Psychiatry, College of Physicians and Surgeons of Columbia University and the OCD Biological Studies Program, NYS Psychiatric Institute, New York, NY, USA
    Search for articles by this author
  • Dan J. Stein
    Footnotes
    Affiliations
    From the Department of Psychiatry, College of Physicians and Surgeons of Columbia University and the OCD Biological Studies Program, NYS Psychiatric Institute, New York, NY, USA
    Search for articles by this author
  • Thomas B. Cooper
    Footnotes
    Affiliations
    From the Department of Psychiatry, College of Physicians and Surgeons of Columbia University and the OCD Biological Studies Program, NYS Psychiatric Institute, New York, NY, USA
    Search for articles by this author
  • Nazrul N. Islam
    Footnotes
    Affiliations
    From the Department of Psychiatry, College of Physicians and Surgeons of Columbia University and the OCD Biological Studies Program, NYS Psychiatric Institute, New York, NY, USA
    Search for articles by this author
  • Michael R. Liebowitz
    Footnotes
    Affiliations
    From the Department of Psychiatry, College of Physicians and Surgeons of Columbia University and the OCD Biological Studies Program, NYS Psychiatric Institute, New York, NY, USA
    Search for articles by this author
  • Donald F. Klein
    Footnotes
    Affiliations
    From the Department of Psychiatry, College of Physicians and Surgeons of Columbia University and the OCD Biological Studies Program, NYS Psychiatric Institute, New York, NY, USA
    Search for articles by this author
  • Author Footnotes
    ∗∗ The authors gratefully acknowledge the performance of biochemical and neuroendocrine assays by Hanna Novacenko, MS, and D. Allen, and the gift of prolactin antibody and standard from the National Pituitary Agency. The authors also acknowledge the help of the pharmacy at the NYS Psychiatric Institute.
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      The present study assesses the timing of and relationship between neuroendocrine response and metabolite blood levels following the partial serotonin (5-HT) agonist m-CPP and the 5-HT releaser/reuptake blocker fenfluramine. Cortisol levels peaked significantly earlier than did prolactin, m-CPP, fenfluramine, or norfenfluramine blood levels by time-to-peak analysis. This earlier cortisol response to both 5-HT agents raises the possibility that peripheral mechanisms may play a role cortisol release. Since peak m-CPP level correlated even more closely to peak prolactin rise than did peak fenfluramine, this suggests that prolactin response to oral m-CPP challenge is useful in assessing 5-HT function.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Asnis G.M.
        • Eisenberg J.
        • Van Praag H.M.
        • Lemus C.Z.
        • Harkavy-Friedman J.M.
        • Miller A.H.
        The neuroendocrine response to fenfluramine in depressives and normal controls.
        Biol Psychiatry. 1988; 24: 117-120
        • Bagdy G.
        • Calogero A.E.
        • Murphy D.L.
        • Szemeredi K.
        Serotonin agonists cause parallel activation of the sympathoadrenomedullary system and the hypothalamo-pituitary-adrencortical axis in conscious rats.
        Endocrinology. 1989; 125: 2664-2669
        • Borroni E.
        • Ceci A.
        • Garratini S.
        • Mennini T.
        Differences between D-fenfluramine and D-norfenfluramine in serotonin presynaptic mechanisms.
        J Neurochem. 1983; 40: 891-893
        • Calogero A.E.
        • Bernardini R.
        • Margioris A.N.
        • Bagdy G.
        • Gallucci W.T.
        • Munson P.J.
        • Tamarkin L.
        • Tomai T.P.
        • Brady L.
        • Gold P.W.
        • Chrousos G.P.
        Effects of serotonergic agonists and antagonists on corticotropin-releasing hormone secretion by explanted rat hypothalami.
        Peptides. 1989; 10: 189
        • Charney D.S.
        • Goodman W.K.
        • Price L.H.
        • et al.
        Serotonin function in obsessive-compulsive disorder: A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects.
        Arch Gen Psychiatry. 1988; 45: 177-185
        • Charney D.S.
        • Woods S.W.
        • Goodman W.K.
        • Heninger G.R.
        Serotonin function in anxiety II: Effects of the serotonin agonist m-CPP in panic disorder patients and healthy controls.
        Psychopharmacology. 1987; 92: 14-24
        • The Clomipramine Collaborative Study Group
        Clomipramine in the treatment of patients with obsessive-compulsive disorder.
        Arch Gen Psychiatry. 1991; 48: 730-738
        • Coccaro E.F.
        • Siever L.J.
        • Klar H.M.
        • Maurer G.
        • Cochrane K.
        • Cooper T.B.
        • Mohs R.C.
        • Davis K.L.
        Serotonergic studies in patients with affective and personality disorders: Correlates with suicidal and impulsive aggressive behavior.
        Arch Gen Psychiatry. 1989; 46: 587-599
        • Costa E.A.
        • Gropetti A.
        • Revuelta A.
        Action of fenfluramine on monoamine stores of rat tissue.
        Br. J Pharmacol. 1971; 41: 57-64
        • Fuller R.W.
        Serotonergic stimulation of pituitary-adrenocortical function in rats.
        Neuroendocrinology. 1981; 32: 118-127
        • Fuller R.W.
        • Snoddy H.D.
        Effect of serotonin-releasing drugs on serum corticosterone concentration in rats.
        Neuroendocrinology. 1980; 31: 96-100
        • Fuller R.W.
        • Snoddy H.D.
        • Macon N.A.
        • et al.
        Dispositions and pharmacological effect of m-CPP in rats.
        Neuropharmacology. 1981; 20: 155-162
        • Fuxe K.
        • Farnebo L.O.
        • Hamberger B.
        • Ogren S.O.
        On the in vivo and in vitro actions of fenfluramine and its derivations on central monoamine neurons especially, 5-hydroxytryptamine neurons, and their relation to the anorectic activity of fenfluramine.
        Postgrad Med J. 1975; 51: 35-45
        • Gibbs D.M.
        • Vale W.
        Effect of the serotonin reuptake inhibitor fluoxetine on corticotropin-releasing factor and vasopressin secretion into hypophyseal portal blood.
        Brain Res. 1983; 280: 176-179
        • Hamik A.
        • Peroutka S.J.
        1-(m-Chlorophenyl)piperazine (m-CPP) interactions with neurotransmitter receptors in the human brain.
        Biol Psychiatry. 1989; 25: 569-575
        • Heninger G.R.
        • Krystal J.H.
        • Smith A.
        Effects of D1 and D2 receptor antagonists and 5-HT receptor agonists and antagonists on neuroendocrine function in rhesus monkeys.
        Abstr Soc Neurosci. 1988; 324: 7
        • Hollander E.
        • DeCaria C.M.
        • Nitescu A.
        • Gully R.
        • Suckow R.F.
        • Cooper T.B.
        • Gorman J.M.
        • Klein D.F.
        • Liebowitz M.R.
        Serotonergic function in obsessive-compulsive disorder: behavioral and neuroendocrine responses to oral m-CPP and fenfluramine in patients and healthy volunteers.
        Arch Gen Psychiatry. 1992; 49: 21-28
        • Hoyer D.
        Functional correlates of serotonin 5-HT-1 recognition sites.
        J Receptor Research. 1988; 8: 59-81
        • Invernizzi R.
        • Cotecchia S.
        • DeBlasi A.
        • Mennini T.
        • Pataccini R.
        • Samanin R.
        Effects of m-chlorphenylpiperzine on receptor binding and brain metabolism of monoamines in rats.
        Neurochem Int. 1981; 3: 239-244
        • Invernizzi R.
        • Kmieciak-Kolada K.
        • Samanin R.
        Is receptor activation involved in the mechanism by which (+)fenfluramie (+)norfenfluramine deplete 5-hydroxytryptophan in the rat brain?.
        Br J Pharmacol. 1982; 75: 525-530
        • Kahn R.S.
        • Asnis G.M.
        • Wetzler S.
        • van Praag H.M.
        Neuroendocrine evidence for serotonin receptor hypersensitivity in panic disorder.
        Psychopharmacology. 1988; 96: 360-364
        • Kaji H.
        • Chihara K.
        • Minamitani N.
        • Kodama H.
        • Kita T.
        • Fujita T.
        Effects of various catecholamine antagonists on prolactin secretion in conscious male rabbits.
        in: Pro Soc Exp Biol Med. 180. 1985: 144-148
        • Lewis D.A.
        • Sherman B.M.
        Serotonergic regulation of prolactin and growth hormone secretion in man.
        Acta Endocrinologica. 1985; 110: 152-157
        • Mueller E.A.
        • Murphy D.L.
        • Sunderland T.
        Neuroendocrine effects of m-CPP, a 5-HT agonist, in humans.
        J Clin Endocrine Metab. 1985; 61: 1179-1184
        • Mueller E.A.
        • Murphy D.L.
        • Sunderland T.
        Further studies of the putative serotonin agonist, m-chlorophenylpiperazine: Evidence for a serotonin receptor mediated mechanism of action in humans.
        Psychopharmacology. 1986; 89: 388-391
        • Pigott T.A.
        • Hill J.L.
        • Grady T.A.
        • L'Heureux F.
        • Bernstein S.
        • Rubenstein C.S.
        • Murphy D.
        A comparison of the behavioral effects of oral versus intravenous m-CPP administration in OCD patient and the effect of metergoline prior to IV m-CPP.
        Biol Psychiatry. 1993; 33: 3-14
        • Pilottle N.S.
        • Porter J.C.
        Dopamine in hypophyseal portal plasma and prolactin in systemic plasma of rats treated with 5-hydroxytryptamine.
        Endocrinology. 1981; 108: 2137-2141
        • Quattrone A.
        • Schettini G.
        • DiRenzo G.
        • Amoroso S.
        • Annunziato L.
        An in vivo useful tool to evaluate the activity of serotonin uptake inhibitors: Prevention by chlorimipramine of the prolactin releasing action of d-fenfluramine.
        Adv Biochem Psychopharmacol. 1982; 31: 229-234
        • Quattrone A.
        • Tedeschi G.
        • Aguglia F.
        • Scopacasa F.
        • DiRenzo G.F.
        • Annunziato L.
        Prolactin secretion in man: A useful tool to evaluate the activity of drugs on central 5-hydroxytryptaminergic neurons: Studies with fenfluramine.
        Br J Clin Pharmacol. 1983; 16: 471-475
        • Rowland N.E.
        • Carlton J.
        Neurobiology of an anorectic drug: Fenfluramine.
        Prog Neurobiol. 1986; 27: 13-62
        • Sanders-Bush E.
        • Conn P.J.
        Neurochemistry of serotonin neuronal systems: consequences of serotonin receptor activation.
        in: Meltzer H.Y. Psychopharmacology: The Third Generation of Progress. Raven Press, New York, NY1987: 95-103
        • Seiver L.J.
        • Murphy D.L.
        • Slater S.
        • de la Vega E.
        • Lipper S.
        Plasma prolactin changes following fenfluramine in depressed patients compared to controls: An evaluation of central serotonergic responsivity in depression.
        Life Sci. 1984; 34: 1029-1039
        • Suckow R.F.
        • Cooper T.B.
        • Kahn R.
        High performance liquid chromatography method for analysis of plasma metachloropiperazine.
        J Chromat. 1990; 528: 228-234
        • Van de Kar L.D.
        • Karteszi M.
        • Bethea C.L.
        • Ganoong W.F.
        Serotonergic stimulation of prolactin and corticosterone secretion is mediated by different pathways from the mediobasal hypothalamus.
        Neuroendocrinology. 1985; 41: 380-384
        • Zohar J.
        • Insel T.R.
        Obsessive-compulsive disorder: Psychobiological approaches to diagnosis, treatment, and pathophysiology.
        Biol Psychiatry. 1987; 22: 667-687